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Molecular genetic aspects of human cancers:
The 1993 Frank Rose Lecture
H.J. Evans
MRC Human Genetics Unit, Western General Hospital, Edinburgh, UK.
The molecular genetics of human cancers clearly covers a
very wide field. In this review therefore, I will aim to provide
a broad perspective, whilst at the same time attempt to
highlight those areas where remarkable advances have been
made and those where they are perhaps to be expected.
I should begin by saying that there is no reason to doubt
that cancer, or cancers, are very much environmentally trig-
gered diseases, as for example we see in the association
between cigarette smoking and lung cancer, but there is also
no reason to doubt that cancer is also very much a genetic
disease. The notion that cancers are genetic diseases goes
back to the turn of the century and in particular to the work
ofTheodore Boveri (1914) who, on the basis of his studies on
abnormalities of growth and development in sea urchins,
concluded that abnormal growth resulting in cancers in
animals were a direct consequence of the occurrence of
chromosome abnormalities. The jump from sea urchins to
mammals is in reality a small one, for, as exemplified by
more recent molecular genetical studies on such diverse
organisms as yeasts, round worms, fruit flies and humans,
the genes that we now know are controlling elements in
cellular proliferation, in differentiation, in programmed cell
death (apoptosis) and organogenesis, have elements in com-
mon in all of these species. It has also been known from
early studies by Paton Rous and others for example, and
later by Bradford Hill and Richard Doll, that carcinogenesis
is a multi-stage process which involves the occurrence of at
least two and possibly as many as four or even more
independent events, a realisation that has been amply
confirmed by more recent molecular studies.
The common human cancers that are of major concern are
cancers that involve epithelial cells such as those lining the
gut, the lungs, cells in the breast and the outer surface layers
of the body. These tissues comprise, and their functions are
dependent on, normal proliferating cells, as indeed is the case
in the bone marrow, and the emergence of a cancer is of
course a consequence of a failure to control cell proliferation.
The tissues I am referring to have a very high cellular tur-
nover rate, for example our dermatologist colleagues tell us
that we completely change our skins once every 6 weeks or
so and there is evidence that we shed and replace some
10,000 million epithelial cells from our colons daily and that
we destroy and replace some 300,000 million blood and
lymphatic cells every 24 h.
The cancers that arise in these tissues are a consequence of
a permanent change, or changes, resulting in an abnormally
continued, or indeed enhanced, proliferative state. We can
look upon these changes as being positive dominant changes
driving the cell into an infinite succession of proliferative
cycles; or as negative changes which result in a failure on the
part of the cell to undergo a normal differentiation or a
normal programmed cell death (Figure 1). Each of these
processes of proliferation, differentiation and programmed
cell death is now clearly known to be governed by a host of
families of specific genes, but the first evidence of a genomic
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mutation that was associated with a specific human malig-
nancy dates back to the work of Peter Nowell and David
Hungerford in Philadelphia in 1960 and their discovery of
the so-called Philadelphia or Ph' chromosome.
Nowell and Hungerford (1960) discovered the consistent
presence of an altered small chromosome, the Ph'
chromosome, in the malignant cells of patients with chronic
myeloid leukaemia (CML), this mutation being absent in the
normal cells of such patients (Figure 2). We now know that
this small abnormal chromosome No 22 is the result of a
reciprocal translocation of a terminal part of chromosome 9
onto the end ofchromosome 22 and the transfer of a slightly
smaller terminal region of chromosome 22 onto chromosome
9 (Figure 3).
The 9/22 translocation in CML involves a breakage at the
5' end of a specific gene, the abl oncogene, on chromosome 9
and the transference of that gene to a breakage site at a gene
called the bcr (breakage cluster region) gene on chromosome
22. The normal product of the abl gene is a 145 kd protein
which has tyrosine kinase activity and is expressed in pro-
liferating cells where it is involved in metabolic pathways
leading to proliferation. The abl gene was originally identified
as the direct counterpart of the oncogenic transforming gene
of the acutely transforming Ableson leukaemia retrovirus, a
virus that produces leukaemia in mice. During its evolution
the virus picked up this gene from a mammal and incor-
porated it into its own genome. The viral form of the gene,
v-abl, is strongly oncogenic in mice, but the normal form of
the abl gene in humans, a proto- or p-oncogene is a gene that
is essential for normal cellular activity. The translocation in
CML results in a mutated cellular oncogene (c-oncogene)
which is an extended gene that is transcribed into a 210 kd
protein. It has recently been shown that sequences within the
first exon of the ber gene are essential for the oncogene
activity of the fusion protein and that this gene has serine/
threonine kinase activity and can phosphorylate several
different protein substrates (Maru & Witte, 1991). It appears
DIFFERENTIATION
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Figure 1 The pathway from stem cells through proliferation to
differentiation and apoptosis.
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Figure 2 Lymphocyte metaphase and karyotype from a
chromosome.
therefore that both the abl gene and the bcr gene may be
involved in a number of intra-cellular signalling pathways
and the upshot of the translocation that brings these two
genes into juxtaposition is that there is a greatly enhanced
tyrosine kinase activity relative to that observed in normal
cells, which then serves to drive these cells containing the
translocation into continued proliferation.
An abnormal abl gene is found in all CML cells, but a Ph'
chromosome is also found in the malignant cells in around
10% of patients with ALL. Here the translocation is at a
slightly different site resulting in a somewhat different fusion
protein with a molecular weight of 190 kd, again having
abnormal tyrosine kinase activity and being strongly
autophosphorylated.
The fact that the abl fusion protein acts in a dominant
oncogenic fashion has been underlined by the work of
Heisterkamp and colleagues (1990) who made mice trans-
genic for a bcr/abl P190 DNA, i.e. the DNA that codes for
the abnormal gene in ALL. It transpired that these mice, in
which the expression of the bcr/abl construct was under the
control of the ber gene promotor, all died during early
patient with CML showing the t9/22 resulting in the Ph'
embryogenesis. However, when the construct was placed
under the control of the metallothionein-I promotor, a pro-
motor for a housekeeping gene, the gene was expressed in all
tissues and eight out of ten surviving transgenic mice died or
were moribund with acute leukaemia between 10 and 28 days
after birth.
One other recent finding of genetic interest in relation to
the bcr/abl translocation is that in 11 cases where the paren-
tal origin of the two involved chromosomes could be unam-
biguously ascertained, in all instances the chromosome 9 (abi
gene) involved the paternally derived chromosome and the
chromosome 22 (bcr gene) the maternally derived homologue
(Haas et al., 1992). This entirely non-random involvement is
also evident in relation to certain inherited tumour predis-
positions and is a phenomenon of considerable current
interest that is associated with inherited genomic imprint-
ing.
Since the discovery of the bcr/abl gene, a series ofexamples
of translocations resulting in the formation of chimaeric
genes which are activated to an oncogenic status have been
described and representatives of these are listed in Table I. ItMOLECULAR GENETIC ASPECTS OF HUMAN CANCERS 1053
turns out that all of these result in fusion proteins which are
transcription factors. In other words, they have two impor-
tant functional regions. One of these is a specific DNA
binding site, a zinc finger or helix-turn-helix region, so that
the protein binds to a specific DNA target site. The other is a
protein binding site, a lucine zipper, which allows dimerisa-
tion with another specific protein that functions as a modu-
lator of transcription. Some of these transcription factors
may act in one or both of two ways, as for example is the
case for the Kruppel gene in Drosophila which codes for a
zinc finger protein. On the one hand the transcription factor
may serve to specifically activate a gene, or genes, required
for differentiation and on the other may act as a specific
repressor of genes required to be expressed in order to main-
tain a proliferative state.
t9:22(q34;ql1) in CML and ALL
x .. : bcr
22
p ~ bcr
c-abl
ph1.
abi = 145k
CML bcr-abl = 210 k fusion
ALL bcr-abl = 190 k |proteins
Figure 3 The translocation in CML and ALL resulting in the
bcr-abl fusion gene.
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An interesting example of a fusion gene is that seen in the
malignant cells of around 30% of children with pre-B ALL
and which involves the tl/19 translocation. The translocation
brings together the PBX-1 gene with its homeobox DNA
binding domain on chromosome 1, and which is probably an
early development gene, and the E2A transcription factor on
chromosome 19 that binds specifically to the enhancer
sequence within the immunoglobulin k complex (Kamps et
al., 1990; Nourse et al., 1990). The PBX-1 gene is not nor-
mally expressed in lymphocytes, but its DNA binding
domain replaces that on E2A so that the powerful positive
signal for lg production is directed at the gene targeted by
the PBX-1 protein so that this gene is expressed at the wrong
time and in the wrong place.
Before leaving our discussion of chromosome transloca-
tions that result in essential oncogene mutations in lymphoid
cells, I should like also to point out that there is a whole
range of other specific translocations in lymphoid cells which
may not, as such, result in mutation in an important regu-
latory gene, but rather affect its regulation by placing that
gene under the control of the promotor of a normally very
active gene in that cell. These translocations are a conse-
quence of errors in the DNA processing by the recombinase
enzyme during the process of normal reshuffling of the V, D
or J regions of the immunoglobulin or T-cell receptor genes
(Table II). The classic example here is Burkitt's lymphoma
which is associated with one of three different translocations
involving chromosome 8 and one of the three immunoglobu-
lin clusters. The consequence of any one of these transloca-
tions is to place the myc oncogene on chromosome 8 juxta-
posed to, and under the control of, the immunoglobulin gene
enhancers. Burkitt's lymphoma is a B-cell neoplasm and a
major function of B-cells is to produce immunoglobulins so
the lg genes are very active. Myc on the other hand is an
early growth response gene. It codes for a nuclear located
protein with a DNA binding helix-loop-helix motif and is a
transcription factor. Its lucine zipper region binds to another
protein called max and the myc/max heterodimer binds to a
palindromic hexamer sequence, CACGTG which is found in
the 5' region of many genes (Blackwood & Eisenman, 1991;
Ayer et al., 1993). The important fact is that the myc gene
turns on a series of genes that are involved in the prolifera-
tion process, so that myc is turned on in proliferating cells
and turned off in quiescent cells.
A second translocation of particular interest is that found
in around 85% of follicular B-cell lymphomas and involves
Table I Some examples of translocations resulting in fusion genes in human malignancies
Malignancy Genes Gene
(translocation) involved structure/function Authors
CML/ALL 9-abl Chimaeric, enhanced Shtivelman et al. (1985)
t(9q/22q) 22-bcr TK activity Hermans et al. (1987)
Walker et al. (1987)
ALL I-PBX-l Chimaeric TF Kamps et al. (1990)
t(lq/19p) 19-E2A Nourse et al. (1990)
APML 15-PML Chimaeric TF Borrow et al. (1990)
t(l5q/17q) 17-RAR de The et al. (1990)
Kakizuka et al. (1991)
AML 6-CAN Chimaeric TF von Lindern et al. (1990)
t(6p/9q)
ALL/AML Chimaeric TF Djabali et al. (1992)
t(l4q/1 lq) I1 -H-TRX-1 (Drosoph trithorax) Gu et al. (1992)
t(n/l lq) Tkachuk et al. (1992)
Ewings 11-HUM FLI-1 Chimaeric TF Delattre et al. (1992)
sarcoma 22-EWS
t(l lq/22q)
Alveolar 2-PAX3 Chimaeric TF Barr et al. (1993)
rhabdomyosarcoma 13-? (Waadenburg syndr)
t(2q/13q)
Mixoid 123-CHOP Chimaeric TF Aman et al. (1992)
liposarcomas 16-?
t(12q/16p)
I
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Table II Chromosome translocations and oncogene activations following aberrant DNA processing in
lymphoid cells
Neoplasm
B-ALL
Burkitt's lymphoma
B-CLL
B-lymphoma
pre B-ALL
T-ALL
Translocation Affected genes
14q32:8q24 IgH:cMYC
2p12:8q24 Igk:cMYC
22q11:8q24 IgA:cMYC
14q32:18q21 IgH:BCL-2
14q32:19q31 IgH:BCL-3
14q32:5q31
14ql1: lp32
14ql 1 :8q24
14qll:10q24
14ql 1:1lpl3
14ql 1:1lpl5
7q35: Ip32
7q35:9q34
7q35:11pl3
7q35: 19pl3
IgH:IL-3
TCR-x/6:TALI
TCR-o/6:c-MYC
TCR-o/b:HOX I1
TCR-a/&:Ttg2
TCR-m/6:Ttgl
TCR-P:TAL1
TCR-P:TAL2
TCR-P:Ttg2
TCR-P:LYLI
p-oncogene function
Transcription factor: cell cycle
ditto
ditto
anti-apoptosis: prolongation of
survival
protein-protein interaction
(= cdc2O): cell cycle
Interleukin 3-lymphokine
DNA/protein binding
transcription factors
the IgH cluster on chromosome 14q32.3, but in this case
translocated to a site on chromosome 18q21. The gene at this
site, the bc12 gene, codes for a small GTP-binding protein
which is located on the surfaces of the nuclear membrane
and the mitochondria (Jacobson et al., 1993). The association
of this bc12 gene with the J segment of IgH results in an
overproduction of the bc12 protein. Normal B cells, of
course, ultimately undergo apoptosis i.e. a form of program-
med, or physiological, cell death (Kerr et al., 1972) which is
characterised by endonuclease mediated DNA fragmentation
and chromosome condensation and depends upon RNA and
protein synthesis in the dying cell (Wyllie, 1993). It is
therefore an active cell-destruct process that is a consequence
of the cell's genetic constitution and its reaction to the
environment. It transpires, however, that the bc12 protein
actively prevents cell death and in the presence of an
activated myc oncogene results in the continuous prolifera-
tion on the part of the B cells (Vaux et al., 1988). The
activated bc12 gene therefore acts as an oncogene and indeed
the insertion of a bc12/Ig construct into a transgenic mouse
results in extending B cell survival in the living animal and in
the formation of follicular lymphomas (Adams & Corey,
1992). This gene therefore exerts its effects through pro-
moting clonal expansion by inhibiting cell death in a popula-
tion of cells that is normally destined to die (Sentman et al.,
1991; Strasser et al., 1991).
The effect of the active bcl gene in preventing programmed
cell death is evident not only in lymphoid cells, but also in
other cell types such as fibroblasts. Studies by Evan et al.
(1992) and Bissonnette et al. (1992) have shown that if c-myc
is turned on in cultured fibroblasts in the presence of growth
factors and in the presence or absence of bc12, the cells
undergo continual proliferation in culture. Similar prolifera-
tion is observed if c-myc and bc/2 are turned on but growth
factors are absent. However, in the absence of growth factors
and bc12 the cells undergo an apoptosis.
Now I have deliberately introduced the findings on activa-
tion of genes to what is essentially a dominant oncogenic
state as a result of chromosome translocation using the lym-
phoid cells as a model, since these cells are readily amenable
to chromosome study and enable us to pinpoint the sites of
mutation by cytogenetic means. However, I must emphasise
that the first isolation and characterisation of cellular
oncogenes was from solid tumours such as, for example, the
Harvey-ras oncogene from human bladder carcinoma cells
(Parada et al., 1982; Der et al., 1982). Since these original
studies there have been a large number of demonstrations
utilising in vitro cell transformation assays to isolate a variety
of proto-oncogenes that have mutated to a transforming
c-oncogenic form in various cell types. These studies have
identified various families of genes which are involved as
growth factors, growth factor receptors, second messengers
and transcription factors, all of which are involved in the
processes leading to cellular proliferation (Table III). As a
result of a great deal of work now on yeast cells and on
mammalian cells in culture, we have also now identified a
whole range of genes involved in the mitotic process (Mur-
ray, 1992). These genes are under the control of other genes
and it is a mutation, or epigenetic change, in these controll-
ing oncogenic genes, following exposure to carcinogenic
agents, that are the important initiating factors in car-
cinogenesis. These studies also serve to underline the fact that
in order to produce a malignant transformation it is neces-
sary to have mutations or alterations in expression of more
than one gene. As indicated earlier the carcinogenic process
requires more than one independent genetic, or epigenetic,
event.
So far I have spent my time talking essentially about genes
whose altered expression acts in a dominant fashion in driv-
ing cells through a continued proliferative state. There are,
however, other genes, so-called tumour suppressor or anti-
oncogenes, which have the reverse effect, namely to prevent
cells proceeding through a proliferative cycle and it has
increasingly become evident that these genes play a very
important role in carcinogenesis.
The first direct evidence that there were such genes as
tumour suppressor genes came from early studies by Henry
Harris and colleagues such as Harold Klinger and Eric Stan-
bridge who showed that the tumorigenicity, in mice, of a
neoplastic human cell with an activated oncogene could be
suppressed if the neoplastic cell was fused to a normal cell.
The fact that such hybrid cells do not give rise to tumours
shows that the action of the active oncogene is suppressed by
one or more introduced normal genes. Now in such hybrid
cells there is usually a loss of donor chromosomes as cells are
maintained in culture, so that the cell, or rather its descen-
Table III Biological functions of some cellular proto-oncogenes
Function Proto-ongogenes
Growth factor sis (PDGF), int-2, hst-1
Growth factor receptor with
TK activity
Tyrosine kinase
erbB (EGF receptor), fms
(CSF receptor), met (HGF
receptor), neu, ros, trk, ret
src, abl, ick, yes
Signal transduction regulation Ha-ras, K-ras, N-ras, gsp, gip
Serine/threonine kinase
Transcription factors
mos, raf
myc, myb, fox, c-jun, relMOLECULAR GENETIC ASPECTS OF HUMAN CANCERS 1055
dants, eventually become neoplastic once more. Studies on
such cells containing the H-rasl activated oncogene show
that neoplasticity is reacquired when the hybrid cell loses its
normal chromosome Ils, so that the effective suppressor
gene must be located on chromosome 11 for this particular
tumour. In more recent studies various workers have intro-
duced a specific gene into a range of neoplastic cells and
shown that some of these genes can completely abrogate the
tumorigenic status of the recipient cell. These studies have
been undertaken on a variety of different tumour types, and I
shall return briefly to some of these shortly.
Going back in historical time I should say that our first
clue to the importance of tumour suppressor genes in human
carcinogenesis stemmed from our studies on the rarer familial
childhood cancers and, in particular, and at least initially,
from studies on retinoblastoma (Knudson, 1971). I would
like to briefly summarise these studies as they provide a
stepping stone to discuss some of the more recent findings
that have been made in our understanding of tumour sup-
pressor genes and inherited cancer predispositions in the
context of the more common human cancers.
Retinoblastoma affects about one in every 18,000 children
and in around 10% of cases it would appear to be inherited.
When it is inherited usually both eyes are affected and there
are often multifocal tumours. In the other 90% of cases the
tumours are sporadic and here usually only one eye is
affected and usually only with one tumour. If we look at the
chromosomes of normal blood or skin cells of individuals
with inherited retinoblastoma then we often find that we see
a small constitutional deletion of part of chromosome 13 at
the q14 locus. In contrast, normal somatic cells of people
with sporadic retinoblastoma have normal chromosomes, but
if we look at the tumour in these people we can often find
the same small deletion of chromosome 13ql4 that we see in
the blood cells of those with the inherited form of the disease
(Francke, 1983).
These general features of retinoblastoma are entirely in line
with an hypothesis put forward by Alfred Knudson about 20
years ago that in an inherited RB a mutational event is
present in, and is. transmitted by, the germ line, so that the
mutation is present in all the derived somatic cells of the
individual. A second mutation then occurs at the same locus
in the homologous chromosome in the retinoblast and this
results in a recessive change in the RB locus and the develop-
ment of a tumour. This second mutation may well be, and
often is, a complete loss of the chromosome bearing the wild
type allele. In sporadic RB both mutations will be somatic
acquired mutations. Knudson's hypothesis has been amply
confirmed (Cavenee et al., 1983) and the RB gene has now
been cloned and characterised (Friend et al., 1986; Lee et al.,
1987). It is a very interesting gene whose product is cyclically
phosphorylated through the action of cyclins (Hinds et al.,
1992) and can be shown to act as a negative controller of
cellular proliferation. It is in an unphosphorylated form in
GO/GI and becomes phosphorylated in the S-phase of the cell
cycle (Buchkovich et al., 1989). In its unphosphorylated form
it binds to one of the proteins involved in cycling the cells
into mitosis, the E2F transcription factor (Chellappan et al.,
1991). This transcription factor activates genes involved in
DNA synthesis such as DHFR, TK and the DNA a poly-
merase and the sequestering of E2F by pRb prevents entry
into S (Nevins, 1992). The absence of Rb, or presence in an
abnormal form, thus prevents it from exerting its down-
regulating effect on the cell cycle. Rb has also been impli-
cated as interacting along the pathway involving c-myc and
also TGF-,I and ,2 in proliferating cells and with myo-D in
the differentiation of muscle cells (Kim et al., 1992; Gu et al.,
1992). More recently three groups (Clarke et al., 1992; Jacks
et al., 1992; Lee et al., 1992) have succeeded in producing
transgenic mice heterozygous for a mutation at the RB-1
locus and these mice develop pituitary tumours rather than
retinoblastomas. Embryos homozygous for the mutation are
inviable, but the transfer of a normal human RB-1 gene into
these embryos corrects the developmental defects.
To underline the importance of the RB mutation I should
point out that it is not merely confined to tumours of the
retina or to osteosarcomas, but it may also occur as an
important mutation in a variety of other human neoplasms.
That the gene is indeed a tumour suppressor gene is evident
by the fact that it is usually absent or abnormal and inactive
in tumour cells. More direct evidence has been provided in
the transgenesis studies and by Huang and colleagues (1988)
who have directly demonstrated that the neoplastic
phenotype of retinoblastoma cells can be suppressed by the
introduction of a normal RB gene into these cells.
The retinoblastoma story is a paradigm indicating how the
inheritance of a defective tumour suppressor gene is respon-
sible for a familial cancer and it has become evident that this
pattern is common to a range of other inherited cancer
predispositions. Table IV lists a number of familial cancers
which appear to be predisposed to by the inheritance of a
single apparently dominant autosomal gene. In all but one of
Table IV Some autosomal dominant inherited cancer predispositions in man
Syndrome Principal tumour Chromosome Locus deletion
(gene) site/tissue and locus in tumour Authors
Retinoblastoma (RBI) Retina, mesenchymal, 13q14 + Cavenee et al. (1983)
osteosarcoma Friend et al. (1986)
Wilms' tumour (WTI) Kidney llpI3 + Fearon et al. (1984)
Porteous et al. (1987)
Familial adenomatous Colorectal 5q21-q22 + Kinzler et al. (1991)
polyposis (APC) adenocarcinoma
von Recklinghausen Neurofibromas, 17q 1.2 + Legius et al. (1993)
neurofibromatosis (NF1) gliomas
Bilateral acoustic Acoustic neuroma, 22qll.l-ql3.1 + Seizinger et al. (1987)
neurofibromatosis (NF2) gliomas Rouleau et al. (1993)
Li Fraumeni (p53) Osteosarcoma, breast, 17pl3.1 + Malkin et al. (1990)
leuk Santibanez-Koref et al. (1991)
Familial breast Breast 17q21-23 + Hall et al. (1990)
and ovarian ca (BRCA21) ovary Int Breast Ca Consort (1993)
Von Hippel-Lindau Renal cell ca, 3pl4-p2l + Seizinger et al. (1988)
(VHL) CNS, pancreas (3p21?) Killary et al. (1992)
Multiple endocrine Pancreas, llq(cent) + Larsson et al. (1988)
neoplasia type I (MENI) pituitary
Multiple endocrine Thyroid IOp I1.2-qI 1.2 - Simpson et al. (1987)
neoplasia type 2A (MEN2A) carcinoma Mathew et al. (1987)1056 H.J. EVANS
these examples it has been clearly demonstrated that in each
case in each of the tumours that develop, the normal homo-
logue of the chromosome with the predisposing mutation is
lost, or the wild type allele has undergone a mutation, so that
the tumour cells are hemi- or homozygous for a mutation at
the predisposing locus. In the first six of these ten examples
the predisposing genes have been isolated and cloned and a
lot is known about their function. I should like to briefly
comment on some of these and also refer to some recent
information on breast cancer.
The Wilms' tumour gene, WT1 codes for two slightly
different proteins, by alternative splicing, both of which are
transcription factors. Homozygous deletion or, as my col-
leagues have shown (Little et al., 1992), mutations within the
zinc finger regions of the gene, results in kidney tumours and
other abnormalities in children; the target to which the pro-
ducts of this gene are directed are, as yet, unknown.
The NFI gene responsible, among other things, for an
inherited predisposition to neurofibromas and indeed sar-
comas, is a large gene coding for a 250 kd protein,
neurofibromin, that has a GTPase-activating - or GAP -
domain, that down regulates ras, an important oncogene that
is a major regulator of growth and differentiation, by
stimulating its intrinsic GRPase activity. Francis Collins and
his colleagues have recently published evidence that NFl is
indeed a tumour suppressor gene by demonstrating homozy-
gous inactivation of the gene in a malignant tumour in a
NFl patient (Legius et al., 1993). Homozygous deletions or
rearrangements of the gene have also been noted in a whole
variety of spontaneous tumours including neuroblastomas
and malignant melanomas (Seizinger, 1993).
The p53 gene is probably the most commonly mutated
gene in all sporadic cancers, it is the subject of intense
world-wide study. The p53 gene codes for a 393 amino-acid
phosphoprotein that is located in the cell nucleus and is
normally expressed at low levels and has a short half life. It
is a transcription factor with a sequence specific DNA bind-
ing region and a transactivation domain and appears to
function as a regulator of genes whose products suppress cell
proliferation. As with pRb, p53 is also complexed in the cell
by the transforming proteins of the oncogenic DNA viruses.
The wild type form of the protein acts as a tumour suppres-
sor as for example the transfection of the wild type gene into
human osteosarcoma cells lacking endogenous p53 complete-
ly abrogates the neoplasticity of the cells (Chen et al., 1990).
Many of the mutant p53 proteins, however, act as dominant
oncogenes so that co-transfection of embryo fibroblasts with
c-myc and many of the mutant p53s results in transformation
whereas co-transfection with c-myc and wild type p53 may
not (Lane & Benchimol, 1990; Levine et al., 1991). A large
number of different point mutations within the gene have
been described and many of these are so-called strong muta-
tions that have a dominant-negative effect - the mutant
protein binding to and inactivating the wild type protein in
cells heterozygous for the mutation (Milner & Medcalf,
1991). Other point mutations are so-called weak mutations
that are not themselves oncogenic in the presence of a wild-
type copy of the gene.
The Li Fraumeni syndrome with its range of different
tumours, sarcomas, breast, gliomas, leukaemias, etc, is
associated with the inheritance of a point mutation in p53
(Figure 4). These mutations are almost certainly 'weak'
mutations, they don't act as dominant negatives, the indivi-
duals that are heterozygous for such mutations develop nor-
mally and indeed a proportion do not develop any cancers.
In the inherited cancer predisposing state therefore these
genes act as recessive tumour suppressors. Indeed p53 is not
an essential modulator of normal cellular proliferation, for
transgenic mice homozygous for knock-out of p53 develop
normally and are viable, but are very prone to a wide range
of tumours (Donehower et al., 1992). Current belief is that
the role of the wild-type protein is to act as a cell cycle G1-S
checkpoint monitor, preventing cells from proceeding
through a cell cycle following exposure to stress and DNA
damaging agents, to allow DNA repair to proceed and main-
L.F. 1
Breast
died age 52
Breast
age 33
±
Malignant Osteogenic Retroperitoneal
glioblastoma sarcoma sarcoma
age 17 age 17 age 1
Figure 4 Family pedigree of a Li-Fraumeni family. The pro-
positus is indicated by an arrow.
taining genomic stability (Lane, 1992; Vogelstein & Kinzler,
1992). There is also recent evidence that the down regulatory
role of the gene may also be involved in the process of
apoptosis (Clarke et al., 1993; Lowe et al., 1993).
Individuals heterozygous for a mutated familial
adenomatous polyposis coli gene, the APC gene (Kinzler et
al., 1991; Joslyn et al., 1991), are characterised by the
development of hundreds, or carpets of thousands, of col-
orectal adenomas some of which develop into frank car-
cinomas. In tumours from these patients the wild type allele
on the normal chromsome is lost or mutated so that the
normal gene appears to act as a tumour suppressor gene and
indeed transfection of a normal chromosome 5 into cultured
neoplastic colorectal cells reverses their neoplasticity.
(Tanaka et al., 1991). The condition is not of frequent occur-
rence, affecting some one in 10,000 individuals, but the gene
is highly penetrant so that approximately 50% of the
offspring of an affected individual develop the disease.
Colon cancer is, of course, one of the commonest of
Western world cancers so that the inheritance of a mutated
APC gene plays virtually no part in most colon cancers. The
work of Vogelstein and colleagues, in particular, however,
has shown that somatic mutation, including loss, of the APC
gene is an important and early event in the development of
so-called sporadic colon cancers (Powell et al., 1992). Dr
Fearon will be discussing some of this work in more detail,
but I should remind you that these studies have characterised
a series of somatic mutations that are causal factors in the
emergence of colon cancer (Figure 5), including of course the
ubiquitous p53, k-ras, MCC and a suppressor gene (DCC)
on chromosome 18 (Fearon et al., 1990).
Now it is well known that there are familial colon cancers
which are not associated with the inheritance of the rare trait
for adenomatous polyps- so called Hereditary Non Poly-
posis Coli Cancer families (Lynch et al., 1985) - where there
is no linkage to any gene on chromosome S or to the p53 or
DCC gene. Indeed various investigators have suggested that
at least 10% or so of colon cancer is predisposed to by the
inheritance of a single mutated gene. In collaboration with
Professors Bird and Wyllie we have attempted to address this
question in Edinburgh by undertaking a detailed family his-
tory of a series of over 800 consecutive colorectal cancer
patients. Our preliminary findings indicate that at least one in
four of our patients had a first degree relative who had
contracted, or had died of, colon cancer. This association
may in part reflect some common environmental factors, but
it also points strongly to a contribution ofinheritance predis-
posing to this disease as being a major factor.
The other very common cancer for which there is evidence
for a predisposing gene or genes which may act as a tumour
suppressor gene is of course breast cancer. Familial forms of
breast cancer have been recognised for well over a century,
and a woman's risk of developing the disease over a given
period is known to be increased some 3-fold if a first degreeMOLECULAR GENETIC ASPECTS OF HUMAN CANCERS 1057
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Figure 5 Known molecular events in colon carcinogenesis (after Fearon et al., 1990).
relative has had breast cancer and by 5- to 10-fold if that
relative had bilateral disease. Recently Marie Clare-King and
colleagues (Hall et al., 1990), and others, have detected a
linkage of familial breast cancer to a gene on chromosome
17q. This linkage is evident in almost all families with breast
and ovarian cancer and perhaps around one-half of these
families with only breast cancer. Bruce Ponder and colleagues
have recently shown that in tumours in such individuals there
is a loss of the chromosome region containing the normal
allele, again indicative of the inherited mutation being in a
tumour suppressor gene (Smith et al., 1992). Our own studies
in Edinburgh confirm and extend these findings (Cohen et
al., 1993) and we have again asked what proportion of breast
cancer patients that we see are part of a breast cancer family.
Our data to date suggest that on the average around 10% of
breast cancer cases are predisposed to by an inherited muta-
tion, with this proportion being age dependent with a much
higher percentage of cases in the younger age group. Some of
these may well be heterozygous carriers of a mutation of the
ataxia telangiectasia gene which Swift and colleagues suggest
may be responsible for around 2% of breast cancer (Heim et
al., 1992). This gene is on chromosome 1llq but has not yet
been isolated.
I have emphasised that all but one of the ten inherited
cancer predispositions listed in Table IV involve the
inheritance of a mutated tumour suppressor gene and the
loss (mutation) of the corresponding wild-type allele in the
neoplasms that eventually arise. Although the cancer predis-
position appears to be inherited as a single apparently
dominant autosomal mutation, it is in fact a recessive muta-
tion which is only expressed as a neoplastic change following
a second somatic event. For cancer predisposing mutations
to be inherited they must obviously not adversely influence
cellular proliferation and differentiation in the developing
embryo and foetus. It is for this reason that most mutations
resulting in the activation or change of function of dominant
c-oncogenes are unlikely to be consistent with viability, for
most p-oncogenes play important roles in the growth,
differentiation and development of the embryo/foetus. In
contrast, in the case of tumour suppressor genes the presence
of one wild-type allele is sufficient to allow normal develop-
ment. The exception in Table IV is the inherited cancer
syndrome known as multiple endocrine neoplasia type 2A
(MEN2A), which is associated with the development of
medullary thyroid carcinoma and phaeochromocytoma. The
predisposing gene for this condition is located at
chromosome 10qll.2, but there is no evidence for loss of
heterozygosity for this region in tumour cells of affected
individuals. Santoro et al. (1990) have shown that the
oncogene ret which maps to this position is overexpressed or
mutated in sporadic thyroid carcinomas and phaeochromo-
cytomas and have suggested that a mutated ret gene may be
responsible for the MEN2A syndrome - a suggestion which
would imply that a mutated ret gene may not be expressed
in, or is of minimal consequence to, the developing
foetus.
Concluding comments
I have attempted to cover a very wide field for it is evident
that cancers are a consequence ofgenetic or epigenetic altera-
tions in a variety of genes that are fundamental to the
processes of growth, cell proliferation, differentiation and
programmed cell removal. In my survey I have deliberately
omitted discussing some interesting and relevant genetic
phenomena such as DNA repair genes, imprinting and
methylation, and I could have spent more time discussing the
flood of knowledge that is emerging from the use of trans-
genic animals to investigate the target genes to which the
transcription factors which are often mutated in cancer are
addressed, as well as the roles played by oncogenes and
suppressor genes in normal development. I hope it is evident
from what I have managed to say, however, that our know-
ledge of the processes involved in carcinogenesis is expanding
rapidly and we would do well to ask where is this knowledge
leading us and how can we apply it for prevention, presymp-
tomatic diagnosis, diagnosis and therapy?
In the fields of cancer prevention and presymptomatic
diagnosis, the isolation of genes that predispose to the
development of familial cancers is really a major step for-
ward, and particularly so in the case of the more common
cancers such as breast cancer. We still need to know, how-
ever, what are the risks associated with the inheritance of a
mutated predisposing gene, and be able to screen those at
risk and advise or treat accordingly. Genetic clinics1058 H.J. EVANS
specifically targetted at breast cancer are being set up around
the country and this is going to result in the practical ap-
plication of some of our basic knowledge on breast cancer to
the benefit of those at high risk. Our knowledge is also going
to raise a number of very important ethical and social ques-
tions and we shall have to proceed with care. We shall also
hear from others at this meeting of the use of oncogene
probes to detect occult early colon cancer by examining
exfoliated colon cells in faeces and of the use of DNA probes
for staging disease. But what of therapy?
The identification of specific oncogenes and tumour sup-
pressor genes and their roles played in oncogenesis provides
us with possible new approaches and new targets for therapy.
Here there is intense interest in following various approaches
and I very broadly classify them into two overlapping
areas.
First the 'immunological area'. This includes approaches
involving the use of humanised antibodies, the use of fusion
protein vaccines, and antibody directed enzyme prodrug
therapies (ADEPT), or virus directed enzyme prodrug
therapy (VDEPT). Ofparticular interest has been approaches
to modulate the immune response of the animal host or
human patient by introducing genes for cytokines, such as
tumour necrosis factor or IL-2, into cancer cells or into
tumour infiltrating lymphocytes and reintroducing these into
the body to stimulate a cytotoxic immune response against
the tumour. A recent interesting development in this area has
been the introduction of immunogenic neoplastic cells expres-
sing antisense growth factor RNA (Trojan et al., 1993).
Much interest has also recently centred on the introduction
of gene coding for a ligand known as B7, a surface molecule
which interacts with the surface molecules (CD28) of
cytotoxic T cells and acts in a costimulatory manner to
activate these killer lymphocytes. Recent studies with B7 on
murine melanoma have been extremely impressive (Townsend
& Allison, 1993), but whether this approach can be transfer-
red to the clinic has yet to be established.
The second area is effectively 'gene targeting and gene
therapy'. The sort of targets that are being discussed here
include the ber/abl fusion gene, p53 and the bc12 gene. The
turning off of a gene that prevents apoptosis has obvious
attractions. The approach being followed is to use syn-
thesised short oligonucleotides, 15-25 bases long, that are
complementary to the sequence of a segment of the DNA of
a gene or to its RNA message. Such anti-sense molecules
which bind to DNA result in triplex structures and block
transcription, similarly antisense RNA blocks translation, so
that the relevant protein is no longer produced. This
antisense approach has been shown to work on tumour cells
in culture and although encouraging results have recently
been reported in in vivo studies on rodents (Simons, et al.,
1992) there is a long way to go yet before it can be shown
that this approach can be effective for example in patients
with resistant non-Hodgkin's lymphoma. Similarly, ap-
proaches using peptides to block oncogene products, e.g. ras
p21, are being talked of, but they are a very long way from
being a practical proposition.
In conclusion I think we can say that we've learnt a great
deal about our genes and how they are aberrant or
misbehave in carcinogenesis, the challenge now is to put this
information to best use in the prevention and treatment of
human cancer.
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